Serglycin CRISPR/Cas9 KO Plasmid (m): sc-422394
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Serglycin CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Serglycin genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Serglycin Antibody (C-11): sc-374657
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Serglycin CRISPR/Cas9 KO Plasmid (m) | sc-422394 | 20 µg | $397.00 |
Overview
Srgn encodes serglycin, a hematopoietic cell–enriched proteoglycan that serves as a scaffold for packaging and storage of proteases, chemokines, and other bioactive mediators within secretory granules. In mouse immune cells, serglycin contributes to granule biogenesis, regulated exocytosis, and extracellular matrix interactions through its chondroitin sulfate–modified core protein. These functions connect Srgn to pathways controlling innate and adaptive immune effector responses, inflammatory signaling, and protease-dependent remodeling. Altered serglycin biology has been implicated in dysregulated immune activation and tumor-associated microenvironmental processes, supporting its relevance in mechanistic studies of inflammation and cancer biology.
Serglycin CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Srgn gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Srgn together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Srgn open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Serglycin protein expression.
This CRISPR knockout system enables efficient generation of Srgn-deficient cell models for investigation of Serglycin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Srgn exon(s) critical for Serglycin function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Srgn genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Serglycin CRISPR/Cas9 KO Plasmid (m) and Serglycin CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Srgn locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Serglycin HDR Plasmid (m) and Serglycin HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Srgn homology arms to support homology-directed repair at defined Srgn target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.